FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160332393> ?p ?o ?g. }

• W2160332393 endingPage "56" @default.
• W2160332393 startingPage "56" @default.
• W2160332393 abstract "<h3>Importance</h3> The presence of tumor-infiltrating lymphocytes at diagnosis is reported to be prognostic in triple-negative breast cancer. <h3>Objective</h3> To evaluate the association of stromal tumor-infiltrating lymphocytes (STILs) with recurrence-free survival (RFS) in women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with chemotherapy or chemotherapy plus trastuzumab in the N9831 trial. <h3>Design, Setting, and Participants</h3> Hematoxylin-eosin–stained tumor slides from patients with early-stage HER2-positive breast cancer in 2 of the 3 arms of the N9831 trial were assessed for STILs at an academic medical center. The amounts of STILs were quantitated in deciles, and a level of at least 60% STILs was used for the prespecified categorical cutoff. The association between STILs and RFS was evaluated with Cox models. <h3>Exposure</h3> Standard chemotherapy consisting of doxorubicin-cyclophosphamide followed by weekly paclitaxel (arm A) or doxorubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab followed by trastuzumab alone (arm C). <h3>Main Outcomes and Measures</h3> Stromal tumor-infiltrating lymphocytes and their association with RFS. <h3>Results</h3> A total of 489 patients from arm A and 456 patients from arm C were assessed with a median (range) follow-up of 4.4 (0-13.6) years. The 10-year Kaplan-Meier estimates for RFS in arm A were 90.9% and 64.5% for patients with high and low levels of STILs, respectively (hazard ratio [HR], 0.23 [95% CI, 0.07-0.73];<i>P</i> = .01). The 10-year estimates for RFS in arm C were 80.0% and 80.1% for patients with high and low levels of STILs, respectively (HR, 1.26 [95% CI, 0.50-3.17];<i>P</i> = .63). The test for interaction between trastuzumab treatment and STIL status was statistically significant (<i>P</i> = .03). In a multivariable analysis, STIL status remained significantly associated with RFS in arm A and not significantly associated in arm C (HR, 1.01 [95% CI, 0.89-1.15]; interaction<i>P</i> = .04). <h3>Conclusions and Relevance</h3> This analysis of participants in the N9831 trial found that the presence of STILs was prognostically associated with RFS in patients treated with chemotherapy alone but not in patients treated with chemotherapy plus trastuzumab. High levels of STILs were associated with lack of trastuzumab therapy benefit, in contrast to a previously reported association between increased levels of STILs and increased trastuzumab benefit in HER2-positive patients. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00005970" @default.
• W2160332393 created "2016-06-24" @default.
• W2160332393 creator A5002510470 @default.
• W2160332393 creator A5006346528 @default.
• W2160332393 creator A5026692399 @default.
• W2160332393 creator A5028893230 @default.
• W2160332393 creator A5065306642 @default.
• W2160332393 creator A5074015095 @default.
• W2160332393 creator A5078606543 @default.
• W2160332393 date "2016-01-01" @default.
• W2160332393 modified "2023-10-17" @default.
• W2160332393 title "Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer" @default.
• W2160332393 cites W1973855239 @default.
• W2160332393 cites W1987234572 @default.
• W2160332393 cites W1988385939 @default.
• W2160332393 cites W1996778928 @default.
• W2160332393 cites W2001198116 @default.
• W2160332393 cites W2009098155 @default.
• W2160332393 cites W2009967743 @default.
• W2160332393 cites W2022205756 @default.
• W2160332393 cites W2034949179 @default.
• W2160332393 cites W2040935952 @default.
• W2160332393 cites W2059589829 @default.
• W2160332393 cites W2098683355 @default.
• W2160332393 cites W2112434826 @default.
• W2160332393 cites W2113499049 @default.
• W2160332393 cites W2120431466 @default.
• W2160332393 cites W2125885282 @default.
• W2160332393 cites W2130034035 @default.
• W2160332393 cites W2130428510 @default.
• W2160332393 cites W2134878729 @default.
• W2160332393 cites W2136573535 @default.
• W2160332393 cites W2146384083 @default.
• W2160332393 cites W2148811436 @default.
• W2160332393 cites W2149908785 @default.
• W2160332393 cites W2157058802 @default.
• W2160332393 cites W2163814095 @default.
• W2160332393 cites W2169914436 @default.
• W2160332393 cites W2560367415 @default.
• W2160332393 doi "https://doi.org/10.1001/jamaoncol.2015.3239" @default.
• W2160332393 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4713247" @default.
• W2160332393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26469139" @default.
• W2160332393 hasPublicationYear "2016" @default.
• W2160332393 type Work @default.
• W2160332393 sameAs 2160332393 @default.
• W2160332393 citedByCount "178" @default.
• W2160332393 countsByYear W21603323932016 @default.
• W2160332393 countsByYear W21603323932017 @default.
• W2160332393 countsByYear W21603323932018 @default.
• W2160332393 countsByYear W21603323932019 @default.
• W2160332393 countsByYear W21603323932020 @default.
• W2160332393 countsByYear W21603323932021 @default.
• W2160332393 countsByYear W21603323932022 @default.
• W2160332393 countsByYear W21603323932023 @default.
• W2160332393 crossrefType "journal-article" @default.
• W2160332393 hasAuthorship W2160332393A5002510470 @default.
• W2160332393 hasAuthorship W2160332393A5006346528 @default.
• W2160332393 hasAuthorship W2160332393A5026692399 @default.
• W2160332393 hasAuthorship W2160332393A5028893230 @default.
• W2160332393 hasAuthorship W2160332393A5065306642 @default.
• W2160332393 hasAuthorship W2160332393A5074015095 @default.
• W2160332393 hasAuthorship W2160332393A5078606543 @default.
• W2160332393 hasBestOaLocation W21603323931 @default.
• W2160332393 hasConcept C121608353 @default.
• W2160332393 hasConcept C126322002 @default.
• W2160332393 hasConcept C143998085 @default.
• W2160332393 hasConcept C207103383 @default.
• W2160332393 hasConcept C2776694085 @default.
• W2160332393 hasConcept C2776755627 @default.
• W2160332393 hasConcept C2779786085 @default.
• W2160332393 hasConcept C44249647 @default.
• W2160332393 hasConcept C530470458 @default.
• W2160332393 hasConcept C71924100 @default.
• W2160332393 hasConceptScore W2160332393C121608353 @default.
• W2160332393 hasConceptScore W2160332393C126322002 @default.
• W2160332393 hasConceptScore W2160332393C143998085 @default.
• W2160332393 hasConceptScore W2160332393C207103383 @default.
• W2160332393 hasConceptScore W2160332393C2776694085 @default.
• W2160332393 hasConceptScore W2160332393C2776755627 @default.
• W2160332393 hasConceptScore W2160332393C2779786085 @default.
• W2160332393 hasConceptScore W2160332393C44249647 @default.
• W2160332393 hasConceptScore W2160332393C530470458 @default.
• W2160332393 hasConceptScore W2160332393C71924100 @default.
• W2160332393 hasIssue "1" @default.
• W2160332393 hasLocation W21603323931 @default.
• W2160332393 hasLocation W21603323932 @default.
• W2160332393 hasLocation W21603323933 @default.
• W2160332393 hasLocation W21603323934 @default.
• W2160332393 hasLocation W21603323935 @default.
• W2160332393 hasOpenAccess W2160332393 @default.
• W2160332393 hasPrimaryLocation W21603323931 @default.
• W2160332393 hasRelatedWork W1722328147 @default.
• W2160332393 hasRelatedWork W2050439103 @default.
• W2160332393 hasRelatedWork W2066747782 @default.
• W2160332393 hasRelatedWork W2316766300 @default.
• W2160332393 hasRelatedWork W2593475799 @default.
• W2160332393 hasRelatedWork W2934076975 @default.
• W2160332393 hasRelatedWork W3177344046 @default.

• next